Leerink Partners Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $27.00

4D Molecular Therapeutics (NASDAQ:FDMT) had its price target lowered by Leerink Partners from $31.00 to $27.00 in a research note published on Monday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Several other brokerages also recently weighed in on FDMT. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday. Bank of America dropped their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Morgan Stanley decreased their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday. Finally, BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $40.00 to $15.00 in a research note on Monday. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Trading Up 3.3 %

Shares of FDMT stock opened at $5.04 on Monday. The firm has a fifty day simple moving average of $6.87 and a 200-day simple moving average of $11.77. The company has a market capitalization of $232.99 million, a PE ratio of -1.77 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $4.68 and a twelve month high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth about $40,000. Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics during the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. raised its stake in 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after acquiring an additional 3,922 shares during the period. Proficio Capital Partners LLC bought a new position in 4D Molecular Therapeutics in the third quarter worth about $108,000. Finally, Marquette Asset Management LLC acquired a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $116,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.